Prescription drug · NDA
Lenvima (Lenvatinib) NDC 62856-720
Lenvatinib 10 mg/1 · Capsule · Oral · Eisai Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 62856-720-30 | 62856072030 | 6 BLISTER PACK in 1 BOX, UNIT-DOSE (62856-720-30) / 10 CAPSULE in 1 BLISTER PACK (62856-720-05)Marketed from Feb 13, 2015 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Lenvima
- Generic name (nonproprietary)
- lenvatinib
- Active ingredients
- Lenvatinib — 10 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Eisai Inc.NDC labeler code 62856
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 206947
- Marketing start
- Listing expires
- Other FDA classes
- Receptor Tyrosine Kinase Inhibitors (Mechanism)
- Identifiers
- Product ID 62856-720_e2339aa3-c753-4269-9c59-1d6528a00f0cSPL ID e2339aa3-c753-4269-9c59-1d6528a00f0cSPL set ID f4bedd21-efde-44c6-9d9c-b48b78d7ed1eRxCUI 1604345, 1604348, 1604349, 1604350, 1604351, 1604352, 1604383, 1604384, 1604394, 1604395, 1792377, 1792392, 1792393, 1796538, 1796664, 1796665, 2054156, 2054157, 2054158, 2054159UNII EE083865G2
- Pharmacologic class
- Kinase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N462856072030followed by a unit qualifier and the quantityPackage 62856-0720-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer (DTC) For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma (RCC) In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma (HCC) For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) En…
Excerpt only. Read the full label for complete information.
About NDC 62856-720
- What is NDC 62856-720?
- 62856-720 is the product NDC for Lenvima (lenvatinib), Lenvatinib 10 mg/1 capsule, listed with the FDA by Eisai Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Lenvima (Lenvatinib).
- What is the active ingredient?
- Lenvatinib.
- Who is the labeler?
- Eisai Inc., NDC labeler code 62856. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Lenvima?
- 7 other product NDCs are listed under this name. See all Lenvima NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Lenvima products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Lenvimalenvatinib | Lenvatinib 4 mg/1 | CapsuleOral | Eisai Inc. | 62856-704 | 62856-0704-30 |
| Lenvimalenvatinib | Lenvatinib 4 mg/1 | CapsuleOral | Eisai Inc. | 62856-712 | 62856-0712-30 |
| Lenvimalenvatinib | Lenvatinib 4 mg/1 | CapsuleOral | Eisai Inc. | 62856-708 | 62856-0708-30 |
| Lenvimalenvatinib | — | Kit | Eisai Inc. | 62856-718 | 62856-0718-30 |
| Lenvimalenvatinib | Lenvatinib 10 mg/1 | CapsuleOral | Eisai Inc. | 62856-710 | 62856-0710-30 |
| Lenvimalenvatinib | — | Kit | Eisai Inc. | 62856-714 | 62856-0714-30 |
| Lenvimalenvatinib | — | Kit | Eisai Inc. | 62856-724 | 62856-0724-30 |
Other NDCs under NDA 206947
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Lenvimalenvatinib | Lenvatinib 4 mg/1 | CapsuleOral | Eisai Inc. | 62856-704 |
| Lenvimalenvatinib | Lenvatinib 4 mg/1 | CapsuleOral | Eisai Inc. | 62856-708 |
| Lenvimalenvatinib | Lenvatinib 10 mg/1 | CapsuleOral | Eisai Inc. | 62856-710 |
| Lenvimalenvatinib | Lenvatinib 4 mg/1 | CapsuleOral | Eisai Inc. | 62856-712 |
| Lenvimalenvatinib | — | Kit | Eisai Inc. | 62856-714 |
| Lenvimalenvatinib | — | Kit | Eisai Inc. | 62856-718 |
| Lenvimalenvatinib | — | Kit | Eisai Inc. | 62856-724 |